Gamida Cell, a Jerusalem, Israel-based provider of cellular and immune therapies for the treatment of cancer and orphan genetic diseases, has been awarded a grant of $3.5m from the Israel Innovation Authority (IIA) of the Israeli Ministry of Economy and Industry.
The grant follows the recent closing of a $40m financing round by the company’s recent establishment of an executive presence in the U.S.
The non-dilutive funding, combined with the round, will support Gamida Cell’s ongoing research and development efforts, including its Phase 3 registration study of NiCord® for hematological malignancies, such as leukemia and lymphoma, its clinical trials of CordIn® for sickle cell disease and thalassemia, and its NK cell therapy for blood and solid cancers.
Led by Dr. Yael Margolin, president and CEO, Gamida Cell is a world leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. The company’s pipeline of products are in development to treat a wide range of conditions including cancer, genetic hematological diseases such as sickle cell disease and thalassemia, bone marrow failure syndromes such as aplastic anemia, genetic metabolic diseases and refractory autoimmune diseases.
Shareholders include Novartis, Clal Biotechnology Industries, Elbit Imaging, Israel Healthcare Ventures, Shavit Capital Fund, VMS Investment Group, Denali Ventures, Auriga Ventures and Israel Biotech Fund.